Medicare to Cover Cost of Provenge
PCF’s Take: The decision today by the Centers for Medicare & Medicaid Services (CMS) to immediately start covering Provenge is good news for many prostate cancer patients with advanced metastatic disease. The Prostate Cancer Foundation began funding research for immunotherapy in the 1990s when many suggested it could not be done. We will continue to fund programs that investigate why immunotherapy works for some patients and not others, as well as programs and that can discover additional therapies that can stimulate the body’s immune system to attack cancer cells.
Read the full story on The Washington Post's website.
PCF Statement About Provenge
Provenge: Understanding the Debate between Selection and Cost